FDA staff signal support for Biogen ALS drug, but highlight data hurdles
Bio Pharma Dive
MARCH 20, 2023
In documents released Monday, agency staff appeared inclined to approve Biogen’s tofersen, which failed in its main trial. Gathering confirmatory evidence of its benefit could be difficult, however.
Let's personalize your content